Previous close | 0.6925 |
Open | 0.6195 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.6195 - 0.6195 |
52-week range | 0.5044 - 1.3300 |
Volume | |
Avg. volume | 462 |
Market cap | 109.551M |
Beta (5Y monthly) | 0.65 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.4800 |
Earnings date | 01 Aug 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 12.50 |
Vaxart, Inc. (NASDAQ:VXRT) shares traded higher in the premarket session on Friday, up more than 23% at one point. Vaxart’s average session volume was about 1.6 million. Friday premarket’s session volume had exceeded four million at the time of writing. Yesterday, Vaxart obtained a project award worth $453 million through the Rapid Response Partnership Vehicle, supported by the Biomedical Advanced Research and Development Authority under the Administration for Strategic Preparedness and Response
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per share. Gross proceeds to Vaxart from the offering are expected to be $40 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Vaxart. The offering is expected to
— 10,000-subject Phase 2b study will evaluate Vaxart’s next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator — — Vaxart anticipates initiating enrollment as early as summer 2024 — SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) announced today that it received a project award valued at up to $453 million through the Rapid Response Partnership Vehicle (RRPV). The RRPV is a Consortium funded by the Biomedical Advanced Rese